'Seeing through a glass darkly': casting light on imidazoline 'I' sites

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• Imidazoline sites have been researched for years, yet their structure, diversity, and physiological roles remain controversial.
• The I1 site is proposed as a binding site influencing systemic blood pressure, but its exact function is unclear.
• Most I2 sites are considered allosteric sites on monoamine oxidase, with their specific functions undetermined despite selective ligands.

Purpose of the Study:

• To review current knowledge on imidazoline sites, including their structure, physiology, and potential endogenous ligands.
• To assess the controversial roles of I1, I2, and I3 imidazoline sites in physiological processes.
• To evaluate the evidence for agmatine as the endogenous ligand 'clonidine-displacing substance'.

Main Methods:

• Literature review of recent data on imidazoline sites.
• Analysis of studies investigating the structure and function of different imidazoline site subtypes (I1, I2, I3).
• Evaluation of research on the endogenous ligand 'clonidine-displacing substance' and potential candidates like agmatine.

Main Results:

• The I1 site's role in blood pressure regulation is still debated.
• I2 sites are linked to monoamine oxidase, but their exact function requires further elucidation.
• The I3 site shows potential as a pharmacologically definable site for modulating insulin secretion.
• Agmatine can displace clonidine but may not fully represent the functional 'clonidine-displacing substance'.

Conclusions:

• Significant controversy persists regarding the structure, diversity, and physiological relevance of imidazoline sites.
• Further research is needed to clarify the exact functions of I1, I2, and I3 sites and to identify the true endogenous ligand.
• Pharmacological definition of the I3 site offers a promising avenue for therapeutic development.